Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant
Sponsor: Albert Einstein Healthcare Network
Summary
This study will evaluate the medication adherence, clinical efficacy, and safety of EnvarsusXR in stable post liver transplant patient using a Phase III randomized controlled study. The primary outcome is change in medication adherence from baseline to the end of the study, assessed using a validated instrument (BAASIS- Basel Assessment of Adherence with Immunosuppressive medication Scales) and standard deviation of Tacrolimus levels.
Official title: A Randomized Controlled Trial to Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
35
Start Date
2017-12-13
Completion Date
2021-12-31
Last Updated
2021-01-08
Healthy Volunteers
No
Conditions
Interventions
EnvarsusXR
Patients randomized to study drug will be converted to EnvarsusXR once daily.
Tacrolimus
Patients continue to take Tacrolimus BID, as a part of routine care.
Locations (1)
Einstein Medical Center
Philadelphia, Pennsylvania, United States